|Post IPO Valuation|
Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals. In the generic pharmaceuticals market, the Company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the Company is developing products for the treatment of central nervous system (CNS) disorders. The Companyâ€™s brand-name product portfolio consists of development-stage projects to which the Company applies its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. It operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division).